20 results about "Leukotriene" patented technology

The present invention relates to a method for assessing whether a subject has Polycystic Ovarian Syndrome (PCOS) or is at risk of developing PCOS, to a method of selecting a patient for therapy of PCOS, to a method for monitoring PCOS progression or for monitoring response to treatment and to a computer-implemented method for assessing a subject with suspected PCOS, by determining the amount or concentration of Leukotriene A4 Hydrolase (LTA4H) in a sample of the subject.

The present invention relates to an external-use powder for treating acute eczema and a preparation method thereof. The external-use powder comprises 96-136 parts by weight of calamine, 1-3 parts by weight of Poria extract, 8-10 parts by weight of Dictamni cortex extract, 3-5 parts by weight of Forsythia suspensa extract, 7-9 parts by weight of Paeonia suffruticosa extract, 5-7 parts by weight of Cnidium monnieri extract, and 0.6-0.85 parts by weight of borneol. The external-use powder of the present invention has a significant therapeutic effect on acute eczema, can significantly inhibit the degree of auricular swelling in an acute eczema mouse model, and improve pathological changes such as epidermal and dermal edema and inflammatory cell infiltration in the mouse auricle tissue; can effectively reduce the toxicity and dosage of calamine, and can improve the safety of calamine; can effectively overcome the adverse aspects and contradictory problems of borneol in regulating allergen-specific immunoglobulin E and leukotriene B4, and can simultaneously reduce serum IgE and LTB4 levels.

The invention belongs to the crossing field of traditional Chinese medicine modernization and biotechnology, and particularly relates to application of a metabolic marker in preparation of a product for auxiliary diagnosis of retinal vein occlusion (RVO) or evaluation of prognosis of treatment of RVO by ginseng-wolfberry omentum granules. The metabolic marker is selected from at least one of the following metabolites: leukotriene B4, (R)-2-feruloyl-1-(4-hydroxyphenyl)-1, 2-ethylene glycol, hyoscyamine base A6, 11, 12-epoxyeicosatrienoic acid, 3, 3 ', 4, 4'-tetrahydroxy-5, 6, 7, 8, 9, 10, 11, 12-epoxyeicosatrienoic acid, 3, 3 ', 4, 4'-tetrahydroxyl-5, 6, 7, 8, 10-tetrahydroxyl-5, 7, 8, 10 The invention relates to an anti-inflammatory agent which is prepared from 5, 5 '-diisopropyl-2, 2'-dimethyl biphenyl (3, 3 ', 4, 4', 1-ethyl piperidine, flavin mononucleotide, crystal orchid glycoside, 2-O-caffeoyl arbutin, dimethyl ellagic acid glucuronide, 4 '-hydroxy-3, 4, 5-resveratrol trimethyl ether, 3'-methoxy petamicin, phenylalanyl-leucyl-isoleucyl-tyrosine and dihydroferulic acid-4-sulfate.

The present application provides the use of leukotrienes in inducing stem cells to differentiate into hematopoietic stem / progenitor cells and the application thereof. According to specific embodiments of the present application, the addition of appropriate amounts of leukotrienes during the process of inducing stem cells to differentiate into hematopoietic stem / progenitor cells can significantly improve the differentiation efficiency of the stem cells into hematopoietic stem / progenitor cells, and significantly increase the number of erythroid cells, megakaryocytic cells, granulocytic cells and mononuclear cells obtained after the differentiation of the stem cells through hematopoietic stem / progenitor cells.

The present invention concerns a composition for use in, or for the treatment of, Rett syndrome, which proposes a repositioning of an anti-asthmatic drug that acts as an antagonist of leukotriene receptors, in particular of the cysteinyl-leukotriene receptor type 1 (CysLTl).

Disclosed is a method of administration and device for the improved bioavailability of leukotriene receptor antagonists. This method and device involve an alkaline surface pH oral film dosage form designed to deliver leukotriene receptor antagonists, such as Montelukast, to the stomach in an amorphous precipitate suspended in aqueous medium. Also disclosed is a device and method for treating a disease, such as a neurodegenerative disease or condition associated with neuroinflammation induced by a leukotriene. The device is a film unit dosage form having an alkaline surface pH film layer and a safe and effective amount of Montelukast. The device is configured and formulated to predominantly achieve enteral delivery of the Montelukast. The method includes enterally delivering to a human or an animal in need of treatment, a safe and effective amount of Montelukast capable of crossing the blood-brain barrier.

This invention is directed to compounds of formula (I):where r, q, R, R2, R3, R4, R5a, R5b, R5c, R6a, R6b, R6c, R7, R8, and R9 are described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, solvates, clathrates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A4 hydrolase inhibitors and therefore useful in treating inflammatory disorders. Pharmaceutical compositions comprising the compounds of the invention and methods of preparing the compounds of the invention are also disclosed.

The application discloses a new use of rape pollen alkali A in nerve protection and brain disease prevention and treatment, discloses beneficial effects and molecular mechanisms of the rape pollen alkali A after the rape pollen alkali A acts on Caenorhabditis elegans, and provides significant differences of three groups (young group, natural aging group and rape pollen alkali A group) of the Caenorhabditis elegans on a transcriptome and a proteome, and reveals potential effects of the rape pollen alkali A on neurodegenerative changes and brain diseases caused by inflammatory substances such as leukotriene B4. The application finds that the rape pollen alkali A improves the pharyngeal pump and body swing of the Caenorhabditis elegans which gradually deteriorate with growth, and significantly improves the oxidative stress capacity of the Caenorhabditis elegans, and preliminarily verifies the effects of the rape pollen alkali A on neurodegenerative changes and brain diseases caused by inflammatory substances such as leukotriene B4 on a model organism. The effects of the rape pollen alkali A in the application are clear, and the rape pollen alkali A has application prospects in nerve protection and brain disease prevention and treatment caused by leukotriene B4.

The invention belongs to the technical field of chemical synthesis of medicines, and particularly relates to a preparation process of azelastine hydrochloride, which comprises four steps of condensation reduction, hydrochloric acid hydrolysis, cyclization and hydrochloric acid salification. According to the method, the reaction efficiency, the product yield and the purity are improved, the production cost and the operation difficulty are reduced, and a stable, cost-controllable and repeatable preparation process is formed. The prepared azelastine hydrochloride is a long-acting anti-allergic drug, has dual effects of resisting histamine and inflammation, has high affinity to a receptor, effectively blocks histamine release of mast cells and basic granulocytes, has wide pharmacological effects on leukotriene, kinin, platelet activating factors and other inflammatory chemical mediators, and can be used for preparing an anti-allergic drug. Therefore, azelastine can effectively relieve typical symptoms of allergic conjunctivitis, such as pruritus, conjunctival congestion, lacrimation, conjunctival edema and the like.

The present invention relates to a method for determining the presence of Mycobacterium bovis in a subject. The method comprises: (i) determining the level of one or more biomarkers in a sample from the subject; and (ii) comparing the level of said one or more biomarkers with the level of said one or more metabolites in a control sample to determine whether Mycobacterium bovis is present in the subject. The biomarkers are selected from: dihydro-leukotriene B4, 3-hydroxyisovaleric acid, sphingomyelin [SM(d18:2(4E,14Z) / 24:0)], sphingomyelin [SM(d18:1 / 24:1(15Z))], 18:3 cholesteryl ester, an unknown compound 389.21933 m / z (under negative ionisation), an unknown compound 886.71063 m / z (under negative ionisation), citric acid, MG(0:0 / 18:3(6Z,9Z,12Z) / 0:0), pyrocatechol, N-(docosanoyl)-heptadecasphing-4-enine-1-phosphocholine and an unknown compound 359.22107 m / z (under negative ionisation).

The invention discloses a nucleic acid composition, an anti-allergic drug associated diagnosis detection kit and a micro-fluidic chip, and relates to the field of allergy detection. The nucleic acid composition disclosed by the invention realizes multi-target cooperative detection through three-section design: the histamine receptor aptamer specifically recognizes the histamine receptor and triggers the change of a stem-loop structure, and the leukotriene receptor response type DNA skeleton enhances the binding stability with the leukotriene receptor through a repetitive sequence; and the drug-triggered auxiliary chain promotes the formation of the complex by prolonging the tail of the poly (adenylic acid). The three components form a cascade reaction, the inflammatory mediator level and the drug responsiveness can be synchronously detected, the detection is more comprehensive than single target detection, and the structural parametric design ensures the suitability and repeatability.

The invention discloses a biomarker for auxiliary diagnosis or evaluation of epilepsy related to nodular sclerosis and application of the biomarker. The biomarker comprises any one or a combination of at least two of a complement component 7, N-acetylgalactosamine transferase 3, an ecological virus integration site 5, a hemoglobin subunit theta 1 or leukotriene A4 hydrolase. The invention provides a protein biomarker combination which is low in invasiveness and easy to quantify and can be used for preoperative evaluation, postoperative prognosis judgment and curative effect monitoring and a detection method thereof, and the accuracy and reliability of nodular sclerosis related epilepsy diagnosis and risk evaluation are remarkably improved.

This invention pertains to the prevention and treatment of aging-associated disease. The invention relates to the use of benzodioxane inhibitors of leukotriene production through modulation of leukotriene A4 hydrolase ("LTA4H") to treat and / or prevent conditions associated with aging such as cognitive disorders, motor disorders, and neuroinflammation.

This invention belongs to the field of animal model analysis technology, specifically relating to a method for establishing a model of gouty rheumatic fever subtypes, the application of a biomarker group, and a detection method. This invention constructs two subtype models of gouty rheumatic fever with more emphasis on dampness and fever with more emphasis on dampness, and establishes a UPLC-MS detection method for serum biomarkers, obtaining a biomarker group including lauroylcarnitine, taurine, palmitoyl-L-carnitine, L-leucine, leukotriene A4, and 13-Oxo-9,11-tridecadienoic acid. Studies show that this biomarker group can simply and effectively distinguish between gouty rheumatic fever with more emphasis on dampness and fever with more emphasis on dampness, and determine the success of model establishment for the two subtypes. Therefore, it can replace conventional characterization and biochemical pathological evaluation methods, improving the objectivity and operability of the assessment.

A pharmaceutical formulation comprising a leukotriene receptor antagonist, a salt or solvate thereof that can be used externally is provided. Specific leukotriene receptor antagonists that can be mentioned include montelukast styrene. The formulations are particularly useful for direct topical administration to treat inflammation, inflammatory disorders and / or conditions characterized by inflammation, including wounds, burns, psoriasis, haemorrhoids, acne and atopic dermatitis.

The present invention addresses the problem of providing a novel cyclic amine derivative or a pharmaceutically acceptable salt or hydrate thereof, and a medicine containing the compound as an active ingredient.　The cyclic amine derivative or a pharmaceutically acceptable salt or hydrate thereof according to the present invention has both an antagonistic effect on histamine and an antagonistic effect on leukotrienes, and is therefore very useful as an active ingredient of a pharmaceutical composition such as a prophylactic and / or therapeutic agent for a wide range of allergic diseases.

Provided is a composition comprising Chlamydomonas reinhardtii or an extract of Chlamydomonas reinhardtii, the Chlamydomonas reinhardtii or the extract of Chlamydomonas reinhardtii comprising an antagonist of a cysteinyl leukotriene receptor.

The invention belongs to the technical field of chemical material engineering, and particularly relates to a vascularization promoting coating and application thereof in a drainage tube. And the vascularization promoting coating comprises linoleic acid and leukotriene D4. The main body material of the drainage tube is PPDO and barium sulfate, and the drainage tube is coated with a PAA hydrogel coating loaded with linoleic acid and leukotriene D4. The PAA hydrogel coating has a pH response mechanism, can intelligently release linoleic acid and leukotriene D4 according to the change of a tissue recovery environment after a pancreatic cancer operation, and promotes vascularization. The biodegradability of the PPDO material reduces the necessity that a patient takes out the drainage tube after a second operation, barium sulfate is used as a developing agent, the degradation condition of the drainage tube can be observed in real time, and the safety and effectiveness of the operation are improved.

The invention discloses an application of amentotaxus biflavone in preparation of a medicine for treating viral sepsis, the amentotaxus biflavone has high affinity to two targets of leukotriene A4 hydrolase (LTA4H) and leukotriene B4 Receptor 1 (Leukotriene B4 Receptor 1, BLT1), can simultaneously inhibit the activity of the LTA4H and the BLT1, and can be used for preparing a medicine for treating the viral sepsis, so that the amentotaxus biflavone can be used for preparing a medicine for treating the viral sepsis. According to the present invention, the virus infection is blocked, the generation of the inflammatory mediator leukotriene B4 mediated by LTA4H is blocked, the inflammatory reaction is amplified by BLT1, the survival rate of the influenza virus infected sepsis mouse model is improved, and the application can be used for preparing the drug for treating viral sepsis.

This invention proposes the use of leukotrienes in promoting the maturation of erythroid cells. According to a specific embodiment of the invention, adding an appropriate amount of leukotrienes during the induction of erythroid cell maturation can effectively promote the maturation of the erythroid cells.